HYCOR Biomedical Announces Senior Executive Appointments

GARDEN GROVE, Calif., July 22 /PRNewswire/ -- HYCOR Biomedical, Inc., a leading manufacturer and marketer of in vitro diagnostic products for the global allergy, autoimmune and urinalysis markets used in clinical laboratories throughout the world, today announced new senior executive appointments as the company continues its transformation into a leading global diagnostics company.  Steve Johnson was named Director of Quality and Regulatory Affairs and Mark Van Cleve as Director of Research and Development.

"Both Steve and Mark are highly skilled executives with significant experience in our industry and we are very pleased that they share our vision in building HYCOR as a global leader in the diagnostics field," said Dick Aderman, CEO of HYCOR.  "We place a high premium on attracting outstanding talent to our new organization and the addition of their respective talents marks another key milestone in the ongoing transformation of HYCOR."

Mr. Johnson comes to HYCOR with more than 25 years of in vitro diagnostics experience with Abbott Laboratories where he worked with Clinical Chemistry, Hematology and Immunoassay products. He has held a series of leadership positions at Abbott, most recently as Site Quality Head and Management Representative at the Abbott - South Pasadena, CA facility. He also served as Manager of Supplier and Operations Quality Assurance, Hematology Customer Support, and Technical Operations.  He is a member of the American Chemical Society (ACS) and American Society for Quality (ASQ).  Mr. Johnson holds a number of certifications, including: ASQ Certified Manager of Quality/Organizational Excellence, ASQ Certified Biomedical Auditor, and ISO 9001 Certified Lead Auditor. Mr. Johnson has a BS in Chemistry from University of Wisconsin - Stevens Point.

Dr. Van Cleve has extensive experience in diagnostics R&D and project management as well as managing R&D teams.  He served with Chiron Corporation (Novartis) from 2000 to 2007 and most recently was Applications Development Manager at Agilent Technologies, Inc., former parent of HYCOR, where he managed process/product engineering and R&D for the HYCOR division and managed a team of scientists. As Principal Scientist at Chiron, he managed R&D teams and project development for a number of Hepatitis B diagnostic kits.  He also spent seven years with BD Bioscience as a Senior Scientist involved in the development of blood diagnostic products. Dr. Van Cleve received his Ph.D. in biochemistry from the University of Illinois at Urbana – Champaign.  He holds a number of patents.

About HYCOR Biomedical, Inc.

Founded in 1981 and based in Garden Grove, California, HYCOR is a global manufacturer and marketer of in vitro diagnostics products. A series of acquisitions since its founding have expanded the company's presence into urinalysis, allergy and autoimmune products used in clinical laboratories, hospitals and doctors' offices worldwide. Among its products, HYCOR markets the HYTEC™, KOVA® and AUTOSTAT™ brands. The company is focused on delivering products that provide the highest value to clinicians through innovation, reliability and customer service.  For more information, please visit www.hycorbiomedical.com.

SOURCE HYCOR Biomedical, Inc.

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED